No Data
No Data
Corning Jerry completes first patient administration in phase I clinical study of HER3/TROP2 dual antibody ADC drug JSKN016
SUZHOU, May 22, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the Phase I clinical study (study number: JSKN016-101) of the HER3/TROP2 dual-antibody ADC drug JSKN016 in patients with advanced malignant solid tumors in China has completed its first patient administration. TROP2 (Trophoblast cell surface antigen 2, human trophoblast cell surface antigen 2) is widely expressed in solid tumors, and its upregulation can promote tumor growth
Corning Jerry Pharmaceutical-B (09966): Phase I clinical trial of JSKN016 to treat advanced malignant solid tumors completed first patient administration
Corning Jerry Pharmaceutical-B (09966) announced that JSKN016 (a human epidermal growth factor independently developed by the company...
Alphamab Oncology's (HKG:9966) 28% Share Price Surge Not Quite Adding Up
Alphamab Oncology (HKG:9966) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses of the
Corning Jerry will first announce Chinese clinical study data on JSKN003 treatment of HER2-expressing solid tumors at the 2024 ASCO Annual Meeting
SUZHOU, May 6, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the company will first announce the Chinese clinical study data (study number: JSKN003-102) of the HER2 double antagonist conjugate drug JSKN003 to treat HER2-expressing solid tumors at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. This year's ASCO Annual Meeting will be held in Chicago, USA from May 31 to June 4, 2024, local time. Topic: Safety and pharmacokinetics of JSKN003 in patients with advanced solid tumors
Alphamab Oncology's 2023 Loss Narrows as Revenue Rises
Alphamab Oncology's (HKG:9966) loss narrowed to 210.6 million yuan, or 0.22 yuan per share, in 2023 from 325.7 million yuan, or 0.35 yuan per share, in 2022, according to the company's annual report f
康寧傑瑞製藥-B:2023年報
No Data